Daito Pharmaceutical: Stock certificate purchase status report (based on section 24-6 (1) of the Act)

Feb 13 02:56 ET

Daito Pharmaceutical: Partial Correction to “First Half, Fiscal Year Ending May 2025 Financial Results Presentation Materials ”

Feb 4 01:30 ET

Daito Pharmaceutical: (Correction) Partial Corrections to the “Financial Results Presentation Materials for the 2nd Quarter of the Fiscal Year Ending 2025/5”

Feb 4 01:30 ET

Daito Pharmaceutical: Notice Regarding Repurchase of Own Shares

Feb 3 03:00 ET

Daito Pharmaceutical: Notice regarding the status of treasury stock repurchases

Feb 3 03:00 ET

Daito Pharmaceutical: Announcement of the release of the financial results briefing “Log Me Finance Transcript” for the 2nd quarter of the fiscal year ending 2025/5

Jan 22 19:30 ET

Daito Pharmaceutical: Partial Correction to “First Half, Fiscal Year Ending May 2025 Financial Results Presentation Materials ”

Jan 22 01:30 ET

Daito Pharmaceutical: (Correction) Partial Corrections to the “Financial Results Presentation Materials for the 2nd Quarter of the Fiscal Year Ending 2025/5”

Jan 22 01:30 ET

Daito Pharmaceutical: Notice regarding our first acquisition of approval for our generic formulation in China

Jan 21 01:30 ET

Daito Pharmaceutical: Interim report.

Jan 17 03:04 ET

Daito Pharmaceutical: First Half, Fiscal Year Ending May 2025 Financial Results Presentation Materials

Jan 15 03:00 ET

Daito Pharmaceutical: Collaboration between Nobel Pharma Co., Ltd. and Daito Co., Ltd. for the development of NPC-29 (ubiquinol-containing formulation with multiple system atrophy (MSA) as an indication)

Jan 15 03:00 ET

Daito Pharmaceutical: Presentation of financial results for the 2nd quarter of the fiscal year ending May 2025

Jan 15 03:00 ET

Daito Pharmaceutical: Confirmation letter.

Jan 10 02:56 ET

Daito Pharmaceutical: Semiannual report - 83rd term (2024/06/01 - 2025/05/31)

Jan 10 02:54 ET

Daito Pharmaceutical: Notice Regarding Absorption-type Merger (Simplified and Short-Form Merger) of a Wholly Owned Subsidiary

Jan 10 01:30 ET

Daito Pharmaceutical: Notice Regarding Stock Split and Partial Amendment to the Articles of Incorporation in Conjunction with the Stock Split

Jan 10 01:30 ET

Daito Pharmaceutical: Notice Regarding Repurchase and Cancellation of Own Shares

Jan 10 01:30 ET

Daito Pharmaceutical: Summary of Consolidated Financial Results for the Six Months Ended November 30, 2024(Under Japanese GAAP)

Jan 10 01:30 ET

Daito Pharmaceutical: Notice regarding the change in position of our representative director

Jan 10 01:30 ET